Identification

Name
Felodipine
Accession Number
DB01023  (APRD00374)
Type
Small Molecule
Groups
Approved, Investigational
Description

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

Structure
Thumb
Synonyms
  • (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
  • 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
  • 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
  • Felodipina
  • Felodipine
  • Felodipinum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felodipineextended-release TabletsTablet, extended release10 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
Felodipineextended-release TabletsTablet, extended release5 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
Felodipineextended-release TabletsTablet, extended release2.5 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
PlendilTablet, extended release2.5 mg/1OralAstra Zeneca Lp1994-10-042016-11-04Us
PlendilTablet, extended release10 mg/1OralAstra Zeneca Lp1991-09-162016-11-04Us
PlendilTablet, extended release5 mg/1OralAstra Zeneca Lp1991-09-162016-11-04Us
PlendilTablet, extended release10 mg/1Oralbryant ranch prepack1991-09-16Not applicableUs
Plendil 10 mgTablet, extended release10 mgOralAstra Zeneca1992-12-31Not applicableCanada
Plendil 2.5 mgTablet, extended release2.5 mgOralAstra Zeneca1994-12-31Not applicableCanada
Plendil 5 mgTablet, extended release5 mgOralAstra Zeneca1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-felodipineTablet, extended release5 mgOralApotex Corporation2016-04-22Not applicableCanada
Apo-felodipineTablet, extended release2.5 mgOralApotex Corporation2016-04-22Not applicableCanada
Apo-felodipineTablet, extended release10 mgOralApotex Corporation2016-04-22Not applicableCanada
FelodipineTablet, film coated, extended release5 mg/1OralPhysicians Total Care, Inc.2005-03-22Not applicableUs
FelodipineTablet, film coated, extended release5 mg/1OralPd Rx Pharmaceuticals, Inc.2004-11-02Not applicableUs
FelodipineTablet, film coated, extended release5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-16Not applicableUs
FelodipineTablet, film coated, extended release10 mg/1OralWockhardt2010-12-05Not applicableUs
FelodipineTablet, extended release5 mg/1OralPar Pharmaceutical2011-12-15Not applicableUs
FelodipineTablet, film coated, extended release2.5 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2010-12-20Not applicableUs68462 0233 01 nlmimage10 1e3e0f60
FelodipineTablet, film coated, extended release2.5 mg/1OralAv Kare, Inc.2014-03-312016-01-15Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Altace Plus Felodipine 2.5mg + 2.5mgFelodipine (2.5 mg) + Ramipril (2.5 mg)TabletOralSanofi Aventis2006-06-272012-10-10Canada
Altace Plus Felodipine 5mg + 5mgFelodipine (5 mg) + Ramipril (5 mg)TabletOralSanofi Aventis2006-06-272012-10-15Canada
International/Other Brands
Felodur ER / Felogard / Penedil / Plendil Depottab (AstraZeneca) / Plendil ER (AstraZeneca) / Plendil Retard (AstraZeneca) / Splendil
Categories
UNII
OL961R6O2C
CAS number
72509-76-3
Weight
Average: 384.254
Monoisotopic: 383.069113515
Chemical Formula
C18H19Cl2NO4
InChI Key
RZTAMFZIAATZDJ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate essential hypertension.

Structured Indications
Pharmacodynamics

Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UCalmodulin
other
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UMineralocorticoid receptor
antagonist
Human
UTroponin C, skeletal muscle
other
Human
UTroponin C, slow skeletal and cardiac muscles
other
Human
Absorption

Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.

Volume of distribution
  • 10 L/kg
Protein binding

99%, primarily to the albumin fraction.

Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

Route of elimination

Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.

Half life

17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.

Clearance
  • 0.8 L/min [Young healthy subjects]
Toxicity

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD50 is 1050 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Felodipine Metabolism PathwayDrug metabolism
Felodipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Felodipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Felodipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Felodipine.Experimental
AcebutololFelodipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Felodipine.Approved
Acetyl sulfisoxazoleThe metabolism of Felodipine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Felodipine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Felodipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Felodipine.Approved, Investigational
AliskirenFelodipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Felodipine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Felodipine.Approved, Withdrawn
AmbrisentanFelodipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineFelodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Felodipine.Approved, Withdrawn
AmiodaroneThe metabolism of Felodipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Felodipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Felodipine.Approved
AmobarbitalThe metabolism of Felodipine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Felodipine.Approved, Investigational
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Felodipine.Approved, Investigational
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Felodipine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Felodipine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Felodipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Felodipine.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Felodipine.Approved, Investigational
ApalutamideThe serum concentration of Felodipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Felodipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Felodipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.Approved
AprepitantThe serum concentration of Felodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Felodipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Felodipine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Felodipine.Approved, Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Felodipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Felodipine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Felodipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Felodipine.Approved
AtomoxetineThe metabolism of Felodipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Felodipine is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Felodipine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Felodipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.Approved, Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Felodipine.Experimental
BarbexacloneThe metabolism of Felodipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Felodipine can be increased when combined with Barbital.Illicit
BarnidipineFelodipine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Felodipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Felodipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Felodipine.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Felodipine.Approved, Investigational
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Felodipine.Approved
BepridilFelodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Felodipine.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Felodipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Felodipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Felodipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Felodipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Felodipine.Approved, Experimental
BisoprololBisoprolol may increase the hypotensive activities of Felodipine.Approved
BoceprevirThe metabolism of Felodipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Felodipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Felodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Felodipine.Approved
BQ-123Felodipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Felodipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.Approved, Investigational
BretyliumFelodipine may increase the hypotensive activities of Bretylium.Approved
BrigatinibThe serum concentration of Felodipine can be decreased when it is combined with Brigatinib.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Felodipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Felodipine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Felodipine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Felodipine.Approved
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Felodipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felodipine.Approved, Investigational
BupranololFelodipine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Felodipine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Felodipine.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Felodipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Felodipine.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Felodipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Felodipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Felodipine.Experimental
CafedrineFelodipine may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Felodipine.Approved
Calcium AcetateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.Approved
CandesartanFelodipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Felodipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Felodipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Felodipine.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Felodipine.Experimental
CaptoprilFelodipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Felodipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Felodipine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Felodipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Felodipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Felodipine.Approved
CarvedilolFelodipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Felodipine.Approved
CeliprololFelodipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Felodipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Felodipine.Approved, Withdrawn
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Felodipine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Felodipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Felodipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Felodipine.Approved
CicletanineFelodipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Felodipine.Approved, Investigational
CilazaprilFelodipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Felodipine.Approved, Investigational
CimetidineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Felodipine.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Felodipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Felodipine can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Felodipine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Felodipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.Approved
CloranololFelodipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Felodipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Felodipine.Approved
CobicistatThe metabolism of Felodipine can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Felodipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Felodipine.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Felodipine.Investigational
CrizotinibThe metabolism of Felodipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Felodipine.Approved
CyclopenthiazideFelodipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Felodipine.Approved, Investigational
CyclosporineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Felodipine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.Approved
DabrafenibThe serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Felodipine.Approved, Investigational
DarunavirThe metabolism of Felodipine can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Felodipine.Approved
DasatinibThe serum concentration of Felodipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Felodipine.Approved, Investigational
DeferasiroxThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilFelodipine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Felodipine can be decreased when combined with Delavirdine.Approved
DeserpidineFelodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Felodipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Felodipine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Felodipine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Felodipine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Felodipine.Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Felodipine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineFelodipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Felodipine.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Felodipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Felodipine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Felodipine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Felodipine.Approved, Investigational
DiltiazemThe metabolism of Felodipine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Felodipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Felodipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Felodipine.Approved, Investigational
DoxycyclineThe metabolism of Felodipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Felodipine can be decreased when combined with Dronedarone.Approved
DuloxetineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Felodipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Felodipine.Approved
EfavirenzThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Felodipine.Approved
EfonidipineFelodipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Felodipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Felodipine.Approved, Vet Approved
EnalaprilatFelodipine may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Felodipine.Approved, Investigational
EndralazineEndralazine may increase the hypotensive activities of Felodipine.Experimental
EnzalutamideThe serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.Approved
EpanololFelodipine may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.Approved
EpoprostenolFelodipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Felodipine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Felodipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Felodipine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Felodipine.Approved, Investigational
ErythromycinThe metabolism of Felodipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Felodipine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Felodipine.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Felodipine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Felodipine.Experimental
Ferulic acidFelodipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Felodipine.Approved, Investigational
FluconazoleThe serum concentration of Felodipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Felodipine.Approved, Investigational
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Felodipine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Felodipine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Felodipine.Approved
FluvoxamineThe metabolism of Felodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Felodipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Felodipine.Approved
FosphenytoinThe metabolism of Felodipine can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Felodipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Felodipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Felodipine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Felodipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Felodipine.Approved
GuanazodineFelodipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineFelodipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Felodipine.Approved, Investigational
GuanoclorFelodipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFelodipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFelodipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Felodipine.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Felodipine.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Felodipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Felodipine.Experimental
HexamethoniumFelodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Felodipine.Approved, Investigational
HexobarbitalThe metabolism of Felodipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Felodipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Felodipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Felodipine.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Felodipine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Felodipine.Approved
IdelalisibThe serum concentration of Felodipine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Felodipine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Felodipine.Approved, Investigational
ImatinibThe metabolism of Felodipine can be decreased when combined with Imatinib.Approved
ImidaprilFelodipine may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Felodipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Felodipine.Approved
IndenololFelodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Felodipine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Felodipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Felodipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Felodipine.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Felodipine.Approved, Investigational
IsavuconazoleThe serum concentration of Felodipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Felodipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Felodipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Felodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Felodipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Felodipine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Felodipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Felodipine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Felodipine.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Felodipine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Felodipine.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Felodipine.Approved, Investigational
KetoconazoleThe serum concentration of Felodipine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Felodipine.Approved
LacidipineFelodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Felodipine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Felodipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Felodipine.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Felodipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felodipine.Approved, Investigational
LevodopaFelodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Felodipine.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Felodipine.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Felodipine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Felodipine.Approved, Vet Approved
LinsidomineFelodipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Felodipine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Felodipine.Approved, Investigational
LofexidineFelodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Felodipine.Approved
LopinavirThe metabolism of Felodipine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Felodipine.Approved, Investigational
LorpiprazoleThe serum concentration of Felodipine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Felodipine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Felodipine.Approved, Investigational
LuliconazoleThe serum concentration of Felodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Felodipine can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Felodipine.Illicit, Investigational, Withdrawn
MacitentanFelodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineFelodipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Felodipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Felodipine.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Felodipine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Felodipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Felodipine.Approved, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Felodipine.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Felodipine.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Felodipine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Felodipine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.Approved
MethohexitalThe metabolism of Felodipine can be increased when combined with Methohexital.Approved
MethoserpidineFelodipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Felodipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Felodipine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Felodipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Felodipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Felodipine can be increased when combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Felodipine.Approved
MetipranololFelodipine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Felodipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Felodipine.Approved, Investigational
MetyrosineFelodipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Felodipine.Experimental
MibefradilFelodipine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Felodipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Felodipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Felodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Felodipine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Felodipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Felodipine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Felodipine.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Felodipine.Approved
MitotaneThe serum concentration of Felodipine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Felodipine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Felodipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Felodipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Felodipine.Vet Approved
MorphineThe metabolism of Morphine can be decreased when combined with Felodipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Felodipine.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Felodipine.Investigational
MuzolimineFelodipine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Felodipine.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Felodipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Felodipine.Approved, Investigational
NadololFelodipine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Felodipine.Approved
NaftopidilFelodipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Felodipine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Felodipine.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Felodipine.Approved, Vet Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Felodipine.Approved
NebivololFelodipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Felodipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Felodipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Felodipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Felodipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Felodipine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Felodipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Felodipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Felodipine.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Felodipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Felodipine.Experimental
NiguldipineFelodipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Felodipine.Investigational
NilotinibThe metabolism of Felodipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineFelodipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Felodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Felodipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Felodipine.Approved
NitrendipineFelodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Felodipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.Approved, Investigational
NitroprussideFelodipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Felodipine.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Felodipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Felodipine.Approved, Vet Approved
ObinutuzumabFelodipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Felodipine.Withdrawn
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Felodipine.Investigational
OlaparibThe metabolism of Felodipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Felodipine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Felodipine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Felodipine.Investigational
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Felodipine.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Felodipine.Experimental
OsimertinibThe serum concentration of Felodipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Felodipine.Approved
OxprenololFelodipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Felodipine.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Felodipine.Investigational
PalbociclibThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Felodipine.Approved
PargylinePargyline may increase the hypotensive activities of Felodipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.Approved
PenbutololFelodipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Felodipine.Approved, Investigational
PentobarbitalThe metabolism of Felodipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumFelodipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Felodipine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Felodipine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Felodipine.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Felodipine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Felodipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Felodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Felodipine.Withdrawn
PhenobarbitalThe metabolism of Felodipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Felodipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Felodipine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Felodipine.Approved, Investigational
PhentolaminePhentolamine may increase the hypotensive activities of Felodipine.Approved
PhenytoinThe metabolism of Felodipine can be increased when combined with Phenytoin.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Felodipine.Approved
PindololPindolol may increase the hypotensive activities of Felodipine.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Felodipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Felodipine.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Felodipine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Felodipine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Felodipine.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Felodipine.Withdrawn
Platelet Activating FactorFelodipine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideFelodipine may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Felodipine.Approved, Investigational
PosaconazoleThe metabolism of Felodipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Felodipine.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Felodipine.Approved
PrazosinPrazosin may increase the hypotensive activities of Felodipine.Approved
PrimidoneThe metabolism of Felodipine can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Felodipine.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Felodipine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Felodipine.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Felodipine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Felodipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Felodipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Felodipine.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Felodipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Felodipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Felodipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Felodipine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Felodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felodipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Felodipine.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Felodipine.Approved, Investigational
RescinnamineFelodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Felodipine.Approved, Investigational
RibociclibThe serum concentration of Felodipine can be increased when it is combined with Ribociclib.Approved, Investigational
RifabutinThe metabolism of Felodipine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Felodipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Felodipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Felodipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Felodipine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Felodipine.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Felodipine.Approved
RisperidoneFelodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabFelodipine may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Felodipine.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felodipine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Felodipine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Felodipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Felodipine.Approved
RucaparibThe metabolism of Felodipine can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Felodipine.Approved
SafrazineSafrazine may increase the hypotensive activities of Felodipine.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Felodipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Felodipine.Approved, Investigational, Vet Approved
SaprisartanFelodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Felodipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Felodipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Felodipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Felodipine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Felodipine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Felodipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Felodipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felodipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Felodipine.Approved
SiltuximabThe serum concentration of Felodipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Felodipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Felodipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Felodipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Felodipine.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Felodipine.Approved, Investigational
SitaxentanFelodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Sorafenib can be decreased when combined with Felodipine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.Approved
SpiraprilFelodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.Approved
St. John's WortThe serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Felodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Felodipine.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Felodipine.Approved
SulfisoxazoleThe metabolism of Felodipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Felodipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
TalinololFelodipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Felodipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Felodipine.Approved, Investigational
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Felodipine.Approved, Investigational
TelaprevirThe metabolism of Felodipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Felodipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Felodipine.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Felodipine.Approved, Investigational
TemocaprilFelodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Felodipine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Felodipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Felodipine.Experimental
TerlipressinFelodipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Felodipine.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Felodipine.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Felodipine.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Felodipine.Approved, Investigational
TetrahydropalmatineFelodipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Felodipine.Approved, Investigational, Withdrawn
TheodrenalineFelodipine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Felodipine.Approved
ThiamylalThe metabolism of Felodipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Felodipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Felodipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Felodipine.Approved
TiboloneFelodipine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Felodipine can be decreased when combined with Ticlopidine.Approved
TicrynafenFelodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Felodipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Felodipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.Approved, Investigational
TocilizumabThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Felodipine.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Felodipine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felodipine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Felodipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Felodipine.Approved, Investigational, Vet Approved
TolonidineFelodipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Felodipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Felodipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Felodipine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Felodipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Felodipine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Felodipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Felodipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Felodipine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Felodipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Felodipine.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Felodipine.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Felodipine.Approved, Investigational
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Felodipine.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Felodipine.Approved, Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Felodipine.Investigational, Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
UnoprostoneFelodipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Felodipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Felodipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Felodipine.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Felodipine.Approved, Investigational
VemurafenibThe serum concentration of Felodipine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Felodipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Felodipine can be decreased when combined with Verapamil.Approved
VincamineFelodipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Felodipine.Approved, Investigational
VinpocetineFelodipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Felodipine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Felodipine.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Felodipine.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Felodipine.Approved
XipamideFelodipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineFelodipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Felodipine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Felodipine.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Felodipine.Approved
ZiprasidoneThe metabolism of Felodipine can be decreased when combined with Ziprasidone.Approved
ZofenoprilFelodipine may increase the hypotensive activities of Zofenopril.Experimental
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Felodipine.Approved
Food Interactions
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

References

Synthesis Reference

Vinay Sharma, "Preparation of micron-size felodipine particles by microfluidization." U.S. Patent US20020086061, issued July 04, 2002.

US20020086061
General References
  1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737]
External Links
Human Metabolome Database
HMDB0015158
KEGG Drug
D00319
PubChem Compound
3333
PubChem Substance
46506968
ChemSpider
3216
BindingDB
189379
ChEBI
585948
ChEMBL
CHEMBL1480
Therapeutic Targets Database
DAP000487
PharmGKB
PA449591
IUPHAR
4190
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Felodipine
ATC Codes
C08CA02 — FelodipineC09BB05 — Ramipril and felodipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (228 KB)
MSDS
Download (55.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentFood-Drug Interactions1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
4CompletedPreventionDisorders Related to Lung Transplantation1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Sexual Dysfunctions1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableUnknown StatusBasic ScienceHigh Blood Pressure (Hypertension) / Insulin Resistance / Microcirculation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • A-S Medication Solutions LLC
  • AstraZeneca Inc.
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • Cardinal Health
  • Heartland Repack Services LLC
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Ranbaxy Laboratories
  • Resource Optimization and Innovation LLC
  • Richmond Pharmacy
  • Sandhills Packaging Inc.
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral2.5 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral2.5 mg/1
Tablet, film coated, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral2.5 mg
Tablet, extended releaseOral5 mg
Prices
Unit descriptionCostUnit
Plendil 10 mg 24 Hour tablet3.17USD tablet
Plendil er 10 mg tablet3.05USD tablet
Plendil 10 mg tablet sa2.96USD tablet
Felodipine 10 mg 24 Hour tablet2.95USD tablet
Plendil er 2.5 mg tablet2.94USD tablet
Felodipine er 10 mg tablet2.72USD tablet
Plendil er 5 mg tablet2.6USD tablet
Plendil 5 mg 24 Hour tablet1.77USD tablet
Plendil 2.5 mg 24 Hour tablet1.76USD tablet
Felodipine 5 mg 24 Hour tablet1.67USD tablet
Plendil 2.5 mg tablet sa1.65USD tablet
Plendil 5 mg tablet sa1.65USD tablet
Felodipine 2.5 mg 24 Hour tablet1.57USD tablet
Felodipine er 2.5 mg tablet1.51USD tablet
Felodipine er 5 mg tablet1.51USD tablet
Renedil 10 mg Extended-Release Tablet1.22USD tablet
Plendil 10 mg Extended-Release Tablet1.15USD tablet
Renedil 5 mg Extended-Release Tablet0.81USD tablet
Plendil 5 mg Extended-Release Tablet0.77USD tablet
Sandoz Felodipine 10 mg Extended-Release Tablet0.73USD tablet
Renedil 2.5 mg Extended-Release Tablet0.6USD tablet
Plendil 2.5 mg Extended-Release Tablet0.57USD tablet
Sandoz Felodipine 5 mg Extended-Release Tablet0.48USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)145 °CNot Available
water solubility19.7 mg/LNot Available
logP3.86SANGSTER (1994)
Caco2 permeability-4.64ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00715 mg/mLALOGPS
logP4.36ALOGPS
logP3.44ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)5.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.63 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.2 m3·mol-1ChemAxon
Polarizability38.04 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9878
Blood Brain Barrier-0.83
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5149
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8664
CYP450 2C9 substrateNon-substrate0.8357
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9304
Ames testNon AMES toxic0.7849
CarcinogenicityNon-carcinogens0.7511
BiodegradationNot ready biodegradable0.9527
Rat acute toxicity2.4526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udu-0139000000-085071c20c5d0c134d8f

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Dichlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compounds
show 5 more
Substituents
Dihydropyridinecarboxylic acid derivative / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, dichlorobenzene, methyl ester, dihydropyridine (CHEBI:585948)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]
  2. Johnson JD, Andrews CT, Khabbaza EJ, Mills JS: The interaction of felodipine with calcium-binding proteins. J Cardiovasc Pharmacol. 1987;10 Suppl 1:S53-9. [PubMed:2442519]
  3. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  4. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559]
  5. Mills JS, Bailey BL, Johnson JD: Cooperativity among calmodulin's drug binding sites. Biochemistry. 1985 Aug 27;24(18):4897-902. [PubMed:4074665]
  6. Walsh MP, Sutherland C, Scott-Woo GC: Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes. Biochem Pharmacol. 1988 Apr 15;37(8):1569-80. [PubMed:2833901]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. [PubMed:18250364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Calcium ion binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC2
Uniprot ID
P02585
Uniprot Name
Troponin C, skeletal muscle
Molecular Weight
18121.895 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF: Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37. doi: 10.1074/jbc.M802180200. Epub 2008 Apr 15. [PubMed:18413310]
  2. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:52